20 completed, 3 recruiting, 2 active not recruiting, 1 not yet recruiting. 20 Phase 1, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 20 | Completed 20 |
| Phase 3 | 6 | Recruiting 3, Active not recruiting 2, Not yet recruiting 1 |
Follow Nerandomilast: new trials by email Literature Review of Nerandomilast trials Research Report on Nerandomilast
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies Placebo, Nerandomilast - Idiopathic Inflammatory Myopathies | Phase 3 | Not yet recruiting | Boehringer Ingelheim | 270 | 2026-12-14 | 2026-10-29 |
| FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression Nerandomilast, Placebo matching nerandomilast - Interstitial Lung Diseases | Phase 3 | Recruiting | Boehringer Ingelheim | 466 | 2026-09-17 | 2026-10-28 |
| A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD) Nerandomilast, Placebo - Fibrosing Interstitial Lung Disease | Phase 3 | Recruiting | Boehringer Ingelheim | 35 | 2026-07-21 | 2026-10-27 |
| A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis Nerandomilast, Placebo - Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities | Phase 3 | Recruiting | Boehringer Ingelheim | 80 | 2026-02-10 | 2026-10-28 |
| A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases Nerandomilast, Placebo matching nerandomilast - Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases | Phase 3 | Active not recruiting | Boehringer Ingelheim | 414 | 2025-09-13 | 2026-10-28 |
| A Study in Healthy Men to Test How Bosentan Influences the Amount of Nerandomilast in the Blood Nerandomilast, Bosentan - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 16 | 2025-08-26 | 2025-10-14 |
| A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Nerandomilast in the Blood nerandomilast, carbamazepine - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 16 | 2025-08-11 | 2025-10-14 |
| A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast Nerandomilast - Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis | Phase 3 | Active not recruiting | Boehringer Ingelheim | 1666 | 2024-09-26 | 2026-10-28 |
| A Study in Healthy People to Compare How 2 Different Low Dose Formulations of BI 1015550 Are Taken up in the Body BI 1015550 - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 64 | 2024-06-06 | 2025-12-01 |
| A Study in Healthy People to Compare How 2 Different High Dose Formulations of BI 1015550 Are Taken up in the Body Nerandomilast - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 64 | 2024-06-04 | 2025-12-01 |
| A Study in Healthy People to Test How BI 1015550 is Taken up in the Body When Given With or Without Food BI 1015550 - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 18 | 2024-05-28 | 2025-12-01 |
| A Study in Healthy People to Test Whether Different Doses of BI 1015550 Have Potential to Induce Heart Rhythm Abnormalities BI 1015550, Moxifloxacin, Placebo - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 46 | 2024-03-06 | 2025-11-28 |
| A Study to Test How Different Doses of Nerandomilast (BI 1015550) Are Taken up in the Body of Healthy Japanese Men Nerandomilast - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 12 | 2023-12-20 | 2025-12-01 |
| A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the Blood BI 1015550, Nintedanib, Pirfenidone - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 14 | 2023-11-08 | 2025-12-02 |
| A Study in Healthy Men to Test How BI 1015550 is Taken up and Handled by the Body BI 1015550, BI 1015550 mixed with [C-14]-BI 1015550 - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 8 | 2023-02-14 | 2025-11-28 |
| A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Kidney Problems BI 1015550 - Renal Insufficiency, Healthy | Phase 1 | Completed | Boehringer Ingelheim | 26 | 2023-02-09 | 2025-11-28 |
| A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Liver Problems BI 1015550 - Hepatic Insufficiency | Phase 1 | Completed | Boehringer Ingelheim | 28 | 2023-02-07 | 2025-11-28 |
| A Study in Healthy Chinese People to Test How Different Doses of BI 1015550 Are Taken up in the Body BI 1015550 - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 24 | 2023-01-13 | 2025-11-28 |
| A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Midazolam in the Blood BI 1015550, midazolam - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 15 | 2022-10-11 | 2025-12-01 |
| A Study in Healthy People to Compare 2 Different Formulations of BI 1015550 Taken With or Without Food Reference (R), Test treatment 1 (T1), Test treatment 2 (T2) - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 24 | 2022-08-15 | 2025-12-19 |
Showing 20 of 26. Sign in to see all of them.
Lung Diseases, Interstitial (3) · Idiopathic Pulmonary Fibrosis (2) · Hepatic Insufficiency (1) · Myositis (1) · Renal Insufficiency (1)
Boehringer Ingelheim (26)
Germany (20) · Netherlands (9) · Japan (8) · United Kingdom (8) · Italy (7) · Spain (7) · Australia (6) · China (6) · France (6) · South Korea (6) · United States (6) · Argentina (5) · Belgium (5) · Canada (5) · Mexico (5)
2023 (5), 2017 (4), 2025 (4)